Aandeel Pharming

Beleggen, aandelen kopen in Nederland, informatie, koersen en analyses



dochter123
Forum veteraan
Forum veteraan
Berichten: 1196
Lid geworden op: 18 apr 2012 10:16
waarderingen: 626

Re: Aandeel Pharming

Bericht door dochter123 »




Gebruikersavatar
Beheerder
Beheerder
Beheerder
Berichten: 7222
Lid geworden op: 01 jan 2012 20:51
waarderingen: 5549
Contacteer:

Re: Aandeel Pharming

Bericht door Beheerder »

dochter123 liked last!
Disclaimer: berichten geplaatst met dit account zijn geen beleggingsadviezen.

Gebruikersavatar
Lieve16
Premiummember
Premiummember
Berichten: 5249
Lid geworden op: 02 jan 2012 22:29
waarderingen: 4801

Re: Aandeel Pharming

Bericht door Lieve16 »

Insiders bij Pharming zien het blijkbaar goed zitten.
https://www.trivano.com/aandeel/pharming.450.insiders
LIEVE liked last!

dochter123
Forum veteraan
Forum veteraan
Berichten: 1196
Lid geworden op: 18 apr 2012 10:16
waarderingen: 626

Re: Aandeel Pharming

Bericht door dochter123 »

Lieve16 schreef:
30 mar 2021 23:02
Insiders bij Pharming zien het blijkbaar goed zitten.
https://www.trivano.com/aandeel/pharming.450.insiders
Ik houd ze in elk geval in mijn port. Sinds de terugkoop van de rechten van Ruconest in de USA zijn de resultaten enkel verbeterd. Een bedrijf met 24 openstaande vacatures.

https://pharming.homerun.co/
LIEVE liked last!

_Jack_
Forum actieveling
Forum actieveling
Berichten: 264
Lid geworden op: 29 jan 2018 20:28
waarderingen: 122

Re: Aandeel Pharming

Bericht door _Jack_ »

Nu is 't verdorie toch al een hele tijd wachten op de 1,5 en dan de volgende terugval naar 0,95.

Gebruikersavatar
ZyppBe
Forum actieveling
Forum actieveling
Berichten: 298
Lid geworden op: 07 sep 2020 14:59
waarderingen: 434

Re: Aandeel Pharming

Bericht door ZyppBe »

Pharming announces enrolment of first patient in multicentre Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction

Clinical trial follows encouraging results from a Phase II, which showed a statistically significant improvement of kidney injury biomarkers in patients undergoing coronary angiography after treatment with RUCONEST®

First patient has been enrolled at the University Hospital Basel, Switzerland, with additional clinical centres in Switzerland to join the study

Leiden, The Netherlands, 22 April 2021

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled in a Phase IIb double-blind, randomized, controlled study to assess the efficacy of RUCONEST® (recombinant human C1 esterase inhibitor, or “rhC1INH”) for the prevention of acute kidney injury after non-ST elevation myocardial infarction at the University Hospital Basel in Basel, Switzerland.

In October 2018, Pharming Group N.V. announced positive results from a Phase II investigator-initiated, double-blind, placebo-controlled clinical trial of RUCONEST® in patients at risk of nephropathy following coronary angiography. The positive results were especially clear in the sub-group of patients undergoing percutaneous coronary interventions such as stent insertions. The intent-to-treat analysis in this group showed that patients on RUCONEST® had a median percentage change in peak urinary neutrophil gelatinase-associated lipocalin within 48 hours, the primary endpoint for the study and a generally-recognized early marker of acute renal injury, of 11.3% in the RUCONEST® arm and 205.2% in the placebo arm (p=0.001). The overall assessment of the study also showed trends that patients undergoing more invasive interventions and procedures requiring higher volumes of contrast medium experienced a stronger benefit from treatment with RUCONEST®.

Following these encouraging results, the Company, in partnership with treating physician Dr Michael Osthoff from the University Hospital of Basel, Switzerland, saw potential for a larger, randomized, controlled multicenter study to investigate the full extent of the role of RUCONEST® in the prevention of acute kidney damage after percutaneous coronary intervention for myocardial infarction. If successful, the clinical trial could also support further development of RUCONEST® to prevent AKI from a wide variety of causes.

Prof. Bruno Giannetti, Pharming’s Chief Medical Officer, commented:
“We are excited to initiate this important study with RUCONEST® and look forward to a swift recruitment rate. The design of this clinical trial allows us to assess important NGAL levels, as well as a large number of clinical and laboratory parameters, which will provide valuable information in, not only, the assessment of acute kidney injury in the setting of myocardial infarction, but eventually across even broader etiologies. If found to be efficacious, RUCONEST® could make a significant contribution to improving the life expectancy and quality of life of patients suffering from kidney damage.”
About the study
The double-blind, randomized, controlled study to assess the efficacy of RUCONEST® for the prevention of acute kidney injury after non-ST elevation myocardial infarction (NSTEMI) will include up to 220 patients. The primary end point is to evaluate the efficacy of rhC1INH compared to placebo after Percutaneous Coronary Intervention (PCI) in NSTEMI patients by examining the peak increase of urinary NGAL (Urinary neutrophil gelatinase-associated lipocalin) within 24 hours following treatment. In addition, the study will seek to identify an appropriate dosing regimen for potential future studies. Additional end points for the study include the incidence of AKI defined by serum creatinine increase within 72 hours after angiography, as well as cardiovascular and renal events and hospitalization-related medical resource utilization for 6 months. The study will be conducted in various centres across Switzerland.

About acute kidney injury
Acute Kidney Injury (AKI) affects approximately 20% of all patients admitted to hospital. It is defined by rapid onset of renal damage and dysfunction. It is an important complication that can impact both short- and long-term patient outcomes. Its incidence may increase to >50% in seriously ill patients or in the presence of risk factors such as chronic kidney disease, diabetes mellitus and nephrotoxic drugs. In the setting of myocardial infarction, AKI can be caused by multiple mechanisms including nephrotoxicity of the contrast agent as well as ischemia-reperfusion injury following PCI.
wolfe liked last!
Core: ABI / ADBE / BABA / DIS / ESPO / FB / ING / PNL / PRX / SQ
Edge: ACPH / ATER / EMBRAC / GLPG / IVA / KAHOT / PAVM / PHARM / PLTR / TDOC / TIGR / U
Cash: 7,2%

dochter123
Forum veteraan
Forum veteraan
Berichten: 1196
Lid geworden op: 18 apr 2012 10:16
waarderingen: 626

Re: Aandeel Pharming

Bericht door dochter123 »

wolfe liked last!

Sjefke Baalmans
Forum actieveling
Forum actieveling
Berichten: 324
Lid geworden op: 29 feb 2016 16:27
waarderingen: 125

Re: Aandeel Pharming

Bericht door Sjefke Baalmans »

Dit aandeel lijkt niet meer van zijn plaats te komen...wellicht de grootste achterblijver op de Nederlandse beurs.
Top of flop...wegwezen dus. :lol:

Gebruikersavatar
Chukky2
Forum veteraan
Forum veteraan
Berichten: 1270
Lid geworden op: 24 jun 2014 21:32
waarderingen: 251

Re: Aandeel Pharming

Bericht door Chukky2 »

Sjefke Baalmans schreef:
22 apr 2021 19:54
Dit aandeel lijkt niet meer van zijn plaats te komen...wellicht de grootste achterblijver op de Nederlandse beurs.
Top of flop...wegwezen dus. :lol:
Als niemand er meer iets in ziet zal het weer gebeuren , let maar op . Er is niets mis met het bedrijf
avantium Bam Bayer-Bioc.Bpost-cresent-econocom -Exmar -Fagron-greenyard-ing-MDxH-Nyrstar -Ontex -Oxurion-Pharming-umic.XFab-Arcelor ,IAsiat-argenx melex -Solvay,AMG,beka.acaci.shel.

Sjefke Baalmans
Forum actieveling
Forum actieveling
Berichten: 324
Lid geworden op: 29 feb 2016 16:27
waarderingen: 125

Re: Aandeel Pharming

Bericht door Sjefke Baalmans »

Er schijnt echt geen einde aan de ellende met dit aandeel te komen. Nu krijgt Biden de schuld. De afgelopen 3/4 jaar is er helemaal niets aan koerswaarde bijgekomen integendeel. Hoe krijg je het voor elkaar. :down:









Plaats reactie